home / stock / ckpt / ckpt news

CKPT News and Press, Checkpoint Therapeutics Inc.

Stock Information
Company Name: Checkpoint Therapeutics Inc.
Stock Symbol: CKPT
Market: NASDAQ
Website: checkpointtx.com
Menu
CKPT CKPT Quote CKPT Short CKPT News CKPT Articles CKPT Message Board
Get CKPT Alerts

News, Short Squeeze, Breakout and More Instantly...
CKPT - Checkpoint resubmits FDA application for cosibelimab

2024-07-02 12:55:12 ET More on Checkpoint Therapeutics Seeking Alpha’s Quant Rating on Checkpoint Therapeutics Historical earnings data for Checkpoint Therapeutics Financial information for Checkpoint Therapeutics Read the full article on Seeking Alp...
CKPT - Checkpoint Therapeutics looks to raise $12M through direct offering

2024-07-02 08:07:43 ET More on Checkpoint Therapeutics Seeking Alpha’s Quant Rating on Checkpoint Therapeutics Historical earnings data for Checkpoint Therapeutics Financial information for Checkpoint Therapeutics Read the full article on Seeking Alp...

CKPT - Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...

CKPT - Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) t...
CKPT - Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its bi...

CKPT - Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat...

CKPT - Checkpoint Therapeutics GAAP EPS of -$0.33

2024-05-10 09:46:10 ET More on Checkpoint Therapeutics Seeking Alpha’s Quant Rating on Checkpoint Therapeutics Historical earnings data for Checkpoint Therapeutics Financial information for Checkpoint Therapeutics Read the full article on Seeking Alp...
CKPT - Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates. ...

CKPT - SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Checkpoint To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 21, 2024) - Faruqi & Faruqi, LLP, a leading nation...

CKPT - DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Checkpoint To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 14, 2024) - Faruqi & Faruqi, LLP, a leading nation...
Next 10